MCID: PRS044
MIFTS: 31

Prostate Sarcoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Prostate Sarcoma

MalaCards integrated aliases for Prostate Sarcoma:

Name: Prostate Sarcoma 12 14 69
Sarcoma of the Prostate 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4054
NCIt 47 C7731
UMLS 69 C0238393

Summaries for Prostate Sarcoma

Disease Ontology : 12 A prostate cancer that is located in the prostate.

MalaCards based summary : Prostate Sarcoma, also known as sarcoma of the prostate, is related to kaposi sarcoma and prostate stromal sarcoma. An important gene associated with Prostate Sarcoma is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Arginine and proline metabolism and Coregulation of Androgen receptor activity. The drugs Fentanyl and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include prostate, t cells and testes.

Related Diseases for Prostate Sarcoma

Graphical network of the top 20 diseases related to Prostate Sarcoma:



Diseases related to Prostate Sarcoma

Symptoms & Phenotypes for Prostate Sarcoma

Drugs & Therapeutics for Prostate Sarcoma

Drugs for Prostate Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
3
Morphine Approved, Investigational Phase 3 57-27-2 5288826
4
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
5
Etanercept Approved, Investigational Phase 2, Phase 3 185243-69-0
6 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
7 Analgesics Phase 3,Phase 2,Phase 1
8 Liver Extracts Phase 3,Phase 1
9 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
10 Analgesics, Non-Narcotic Phase 2, Phase 3,Phase 1
11 Antirheumatic Agents Phase 2, Phase 3,Phase 1
12 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
13 Adjuvants, Anesthesia Phase 3
14 Analgesics, Opioid Phase 3
15 Anesthetics Phase 3,Phase 2
16 Anesthetics, General Phase 3
17 Anesthetics, Intravenous Phase 3
18 Central Nervous System Depressants Phase 3
19 Narcotics Phase 3
20 Epoetin alfa Phase 3 113427-24-0
21 Antineoplastic Agents, Hormonal Phase 3,Phase 2
22 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
23 Anti-Inflammatory Agents Phase 2, Phase 3
24 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
25 Cola Nutraceutical Phase 3,Phase 1,Phase 2
26
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
27
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
28
Lorazepam Approved Phase 2 846-49-1 3958
29
Ifosfamide Approved Phase 2 3778-73-2 3690
30
Mechlorethamine Approved Phase 2 51-75-2 4033
31
Mesna Approved Phase 2 3375-50-6 598
32
Leuprolide Approved, Investigational Phase 2 53714-56-0 3911 657181
33
Propranolol Approved, Investigational Phase 1, Phase 2 525-66-6 4946
34
Docetaxel Approved May 1996, Investigational Phase 1, Phase 2 114977-28-5 148124 9877265
35
Alvocidib Experimental, Investigational Phase 2 146426-40-6, 131740-09-5 5287969
36
Tremelimumab Investigational Phase 1, Phase 2 745013-59-6
37 Albumin-Bound Paclitaxel Phase 1, Phase 2
38 Antibodies Phase 1, Phase 2
39 Antibodies, Monoclonal Phase 1, Phase 2
40 Antimitotic Agents Phase 1, Phase 2
41 Antineoplastic Agents, Phytogenic Phase 1, Phase 2
42 Immunoglobulins Phase 1, Phase 2
43 Interleukin-2 Phase 1, Phase 2
44 Alkylating Agents Phase 2,Phase 1
45 Androgens Phase 1, Phase 2
46 Protein Kinase Inhibitors Phase 2,Phase 1
47 Anti-Infective Agents Phase 1, Phase 2
48 Antiviral Agents Phase 1, Phase 2
49 Vaccines Phase 1, Phase 2
50 Isophosphamide mustard Phase 2

Interventional clinical trials:

(show top 50) (show all 77)

id Name Status NCT ID Phase Drugs
1 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
4 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3 octreotide acetate
5 Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia Terminated NCT00127387 Phase 2, Phase 3 Enbrel
6 Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients Unknown status NCT01134250 Phase 1, Phase 2 F16IL2 in combination with paclitaxel
7 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
8 Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00005974 Phase 2 alvocidib
9 Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases Completed NCT00587964 Phase 2
10 Ph II Cabazitaxel DD Liposarcoma Recruiting NCT01913652 Phase 2 Cabazitaxel;Prolonged infusional ifosfamide
11 Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies Recruiting NCT02900651 Phase 1, Phase 2 MAK683
12 A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting NCT02643303 Phase 1, Phase 2 Durvalumab;Tremelimumab;Poly ICLC
13 Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer Active, not recruiting NCT02274779 Phase 2 ELIGARD
14 Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Tria Not yet recruiting NCT02732678 Phase 1, Phase 2 PROPRANOLOL
15 Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer Withdrawn NCT01065441 Phase 1, Phase 2
16 Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies Completed NCT00703625 Phase 1 Temsirolimus;Docetaxel
17 AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma Completed NCT00562380 Phase 1
18 Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies Completed NCT00703170 Phase 1 Temsirolimus;Pegylated liposomal doxorubicin
19 A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors Completed NCT01608867 Phase 1
20 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1 docetaxel;gemcitabine hydrochloride
21 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
22 NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Completed NCT00199849 Phase 1
23 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
24 Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors Completed NCT00620295 Phase 1 bortezomib;gemcitabine hydrochloride
25 Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Completed NCT01522820 Phase 1 Sirolimus
26 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1 tanespimycin
27 Spectroscopy With Surface Coils and Decoupling Completed NCT00581815 Phase 1
28 Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. Completed NCT00423254 Phase 1
29 Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Completed NCT01286987 Phase 1 Talazoparib
30 Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Completed NCT00161187 Phase 1
31 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
32 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00083213 Phase 1
33 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00082823 Phase 1
34 Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer Completed NCT00003704 Phase 1 capecitabine
35 A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen Completed NCT00623831 Phase 1
36 Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors Completed NCT00703638 Phase 1 cisplatin;pemetrexed disodium;sorafenib
37 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1 vorinostat
38 A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors Completed NCT00465725 Phase 1 Picoplatin
39 Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1 Completed NCT01234012 Phase 1
40 To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Solid Tumors Recruiting NCT03159585 Phase 1 Cyclophosphamide
41 Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Recruiting NCT01642342 Phase 1
42 NY-ESO-1 TCR (TAEST16001)for Patients With Advanced NSCLC Recruiting NCT03029273 Phase 1 Cyclophosphamide
43 A Study Evaluating MM-310 in Patients With Solid Tumors Recruiting NCT03076372 Phase 1 MM-310
44 Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Recruiting NCT01638533 Phase 1 Romidepsin
45 Safety Study of MGD009 in B7-H3-expressing Tumors Recruiting NCT02628535 Phase 1
46 Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies Recruiting NCT02223052 Phase 1 CC-486;Vidaza
47 Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Active, not recruiting NCT02014337 Phase 1 Mifepristone and Eribulin in combination
48 Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. Active, not recruiting NCT01353625 Phase 1 CC-115
49 EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma Terminated NCT00004261 Phase 1 EF5
50 Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer Terminated NCT00288444 Phase 1 Lonafarnib;Docetaxel

Search NIH Clinical Center for Prostate Sarcoma

Genetic Tests for Prostate Sarcoma

Anatomical Context for Prostate Sarcoma

MalaCards organs/tissues related to Prostate Sarcoma:

39
Prostate, T Cells, Testes, Breast, Bone, Liver, Brain

Publications for Prostate Sarcoma

Articles related to Prostate Sarcoma:

(show all 12)
id Title Authors Year
1
Primary prostate sarcoma: how to manage following diagnosis at transurethral resection. ( 27147716 )
2016
2
Multimodal Therapy in the Treatment of Prostate Sarcoma: The Johns Hopkins Experience. ( 26003268 )
2015
3
Prostate sarcoma: report of 2 cases and bibliographic review. ( 25306988 )
2014
4
Adult prostate sarcoma: the Memorial Sloan Kettering experience. ( 25168544 )
2014
5
Stromal prostatic sarcoma: a rare tumor with rare clinical and imaging presentation. ( 24421945 )
2013
6
Twenty-five cases of adult prostate sarcoma treated at a high-volume institution from 1989 to 2009. ( 23601444 )
2013
7
Adult prostate sarcoma: radiological-clinical correlation. ( 19103347 )
2009
8
[Adult prostate sarcoma: a report of 6 cases with clinical analysis]. ( 17725305 )
2007
9
Adult prostate sarcoma diagnosed from tissue spontaneously excreted through the urethra. ( 15082008 )
2004
10
Adult prostate sarcoma: the M. D. Anderson Cancer Center Experience. ( 11458058 )
2001
11
MRI of radiation-induced prostate sarcoma. ( 7895201 )
1995
12
Unilateral nerve-sparing radical prostatectomy and hemicystectomy in management of prostate sarcoma. ( 8470313 )
1993

Variations for Prostate Sarcoma

Expression for Prostate Sarcoma

Search GEO for disease gene expression data for Prostate Sarcoma.

Pathways for Prostate Sarcoma

GO Terms for Prostate Sarcoma

Biological processes related to Prostate Sarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 creatine metabolic process GO:0006600 8.62 CKB CKM

Molecular functions related to Prostate Sarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transferase activity, transferring phosphorus-containing groups GO:0016772 8.96 CKB CKM
2 creatine kinase activity GO:0004111 8.62 CKB CKM

Sources for Prostate Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....